Abstract
Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Current Pharmaceutical Biotechnology
Title: Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Volume: 1 Issue: 1
Author(s): Ignacio Perez-Roger, Carmen Ivorra, Antonio Diez, Maria Jose Cortes, Enric Poch, Silvia M. Sanz-Gonzalez and Vicente Andres
Affiliation:
Keywords: Inhibition, Cellular proliferation, Drug targeting, Cyclin dependent kinases, Chemical inhibitors, Purines
Abstract: Abnormal cellular proliferation is associated with the pathology of several diseases, including cancer, atherosclerosis and restenosis post-angioplasty. Therefore, anti-proliferative therapies may be a suitable approach to treat these disorders. Candidate targets for such strategies include specific components of the cell cycle machinery. Progression through the cell cycle in mammalian cells requires the activation of several cyclin-dependent protein kinases (CDKs) through their association with regulatory subunits called cyclins. Active CDK/cyclin holoenzymes phosphorylate cellular proteins including the retinoblastoma susceptibility gene product (pRb) and the related pocket proteins p107 and p130. Several compounds have been described that directly or indirectly inhibit the activity of CDKs, which results in a suppression of cell growth. In this review, we will discuss the use of drugs targeting CDKs and their therapeutic application in animal models and clinical trials.
Export Options
About this article
Cite this article as:
Perez-Roger Ignacio, Ivorra Carmen, Diez Antonio, Cortes Jose Maria, Poch Enric, Sanz-Gonzalez M. Silvia and Andres Vicente, Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases, Current Pharmaceutical Biotechnology 2000; 1 (1) . https://dx.doi.org/10.2174/1389201010001010107
DOI https://dx.doi.org/10.2174/1389201010001010107 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Is Senescence Reversible?
Current Drug Targets Recent Patents on Melanoma with Focus on Genetic Strategies
Recent Patents on Anti-Infective Drug Discovery Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Discovering Tumor Suppressor Genes Through Genome-Wide Copy Number Analysis
Current Genomics Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets MicroRNAs and Pancreatic Cancer: Current Research and Future Outlooks
Current Signal Transduction Therapy NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy The Meaningful Function of the Emerging Clinical Targets-lncRNA MEG3 in Gastric Cancer
Current Pharmaceutical Design Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Non-canonical Functions of Telomerase Reverse Transcriptase: Emerging Roles and Biological Relevance
Current Topics in Medicinal Chemistry Integrated, Molecular Engineering Approaches to Develop Prostate Cancer Gene Therapy
Current Gene Therapy The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction
Current Medicinal Chemistry